Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Cancer Immunol Immunother · 2025 · PMC12715071 · PMID 41410741

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.188not close (p > 0.1)

showed a trendno p-value reported

In contrast, among patients without MPR, adjuvant therapy showed a trend toward better DFS, although this did not reach statistical significance ( p = 0.188).

also in 53,322 other papers

an encouraging trendno p-value reported

Our study revealed an encouraging trend in both DFS and OS within the adjuvant treatment cohort, during the early stage, which persisted throughout the observation period.

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.